Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05117242 |
|
Recruitment Status :
Recruiting
First Posted : November 11, 2021
Last Update Posted : April 3, 2024
|
Sponsor:
Genmab
Collaborators:
BioNTech SE
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Genmab
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | November 2024 |
| Estimated Study Completion Date : | March 2027 |